Search results
Showing 101 to 150 of 3807 results for treatment
In development Reference number: GID-TA11898 Expected publication date: TBC
Thermocoagulation for the treatment of piles and anal fistula
Topic prioritisation
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)
Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
Agomelatine for the treatment of major depressive episodes (terminated appraisal) (TA231)
NICE is unable to recommend the use in the NHS of agomelatine for the treatment of major depressive episodes. This is because Servier did not provide an evidence submission.
Show all sections
Sections for TA231
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
View recommendations for TA121Show all sections
Electrocautery cutting balloon treatment for pelviureteric junction obstruction
Topic prioritisation
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.
NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia. This is because Lilly did not provide an evidence submission
Show all sections
Sections for TA273
Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
Cryotherapy as a primary treatment for prostate cancer (HTG91)
Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.
View recommendations for HTG91Show all sections
Sections for HTG91
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)
Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults.
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)
Evidence-based recommendations on using an ozone-releasing device (HealOzone) in people with tooth decay.
Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
Evidence-based recommendations on electrotherapy for treating grade I to III haemorrhoids in adults. This involves using electric current to shrink the haemorrhoids.
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation
Topic prioritisation
Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Evidence-based recommendations on rucaparib (Rubraca) for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Transcatheter valve-in-valve implantation for the treatment of Tricuspid valve
Topic prioritisation
An aortic cuff counterpulsation system for the treatment of heart failure
Topic prioritisation
NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. This is because Wyeth did not provide an evidence submission.
Show all sections
Sections for TA207
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over.
Evidence-based recommendations on cryotherapy for the treatment of liver metastases. This involves using cold temperatures applied through a special needle to destroy the cancer cells.
View recommendations for HTG241Show all sections
Sections for HTG241
Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)
Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.
EchoLaser percutaneous laser ablation treatment for patients with neck lesions
Topic prioritisation
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Evidence-based recommendations on rituximab for treating relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma in adults.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.